TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23314743
Drug: LCI699 (0.5-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (0.5-1 mg b.i.d.)
Study: 22108151
Drug: Ezetimibe/simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin (10/20 or 10/40 mg)
Study: 22108151
Drug: Atorvastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10, 20, or 40 mg)
Study: 22108151
Drug: Ezetimibe/simvastatin (10/20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin (10/20-40 mg)
Study: 22108151
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses (ezetimibe/simvastatin and atorvastatin)
Study: 30939085
Drug: Hypnotic intervention
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic intervention
Study: 15166915
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba special extract EGb 761 (2 x 120 mg/day for 7 days)
Study: 9713935
Drug: diphtheria‐tetanus‐acellular pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphtheria‐tetanus‐acellular pertussis (dTap) vaccine
Study: 9713935
Drug: diphtheria‐tetanus (dT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphtheria‐tetanus (dT) vaccine
Study: 2840652
Drug: Metoclopramide (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (doses adjusted to each individual case)
Study: 20677606
Drug: 5.0% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0% lignocaine 75 mg
Study: 20677606
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 12.5 mg
Study: 26578422
Drug: Brimonidine/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine/timolol fixed combination (BTFC)
Study: 17571086
Drug: Unfixed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfixed combination of brimonidine and timolol
Study: 16648043
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (20 mg/kg bodyweight)
Study: 6382004
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg twice a day
Study: 6382004
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg twice a day
Study: 26804670
Drug: 5-alpha reductase
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-alpha reductase inhibitors (5-ARIs)
Study: 24607046
Drug: MP29-02, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP29-02, one spray per nostril twice daily (total daily doses of azelastine hydrochloride and FP were 548 mcg and 200 mcg, respectively)
Study: 24607046
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 2 sprays per nostril once daily (total daily dose 200 mcg)
Study: 22396230
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia (TH) using cloth covered cooling gel packs for 72 hours
Study: 20178792
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue injections (n = 36)
Study: 8701480
Drug: Inhalation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation therapy with magnesium sulfate
Study: 8701480
Drug: Inhalation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation therapy with salbutamol sulfate
Study: 6859073
Drug: Nitrates (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates (large doses)
Study: 6859073
Drug: Long-term nitrate
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term nitrate therapy
Study: 26910903
Drug: MRI-guided laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided laser interstitial thermal therapy (laser ablation)
Study: 24744317
Drug: FA plus
Normalized name: Medorfa Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA plus 30 mg of iron (IFA)
Study: 24744317
Drug: FA plus
Normalized name: Medorfa Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA plus 30 mg of iron (IFA) and FA, iron, plus 13 additional micronutrients (MM)
Study: 22185768
Drug: Passive Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Movement Therapy (PMT) three times a week for four weeks
Study: 17492901
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities for chronic pelvic pain
Study: 15644655
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg twice daily
Study: 4061020
Drug: Suxamethonium during
Normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suxamethonium during halothane inhalation in group I (children under 10)
Study: 4061020
Drug: Suxamethonium during
Normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suxamethonium during halothane inhalation in group II (children over 10)
Study: 4061020
Drug: Suxamethonium during
Normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suxamethonium during halothane inhalation in group III (children over 10)
Study: 4061020
Drug: Pancuronium and
Normalized name: pancuronium
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium and thiopentone during intravenous induction in group III (children over 10)
Study: 30843873
Drug: Transcutaneous (t.c.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous (t.c.) administration of trivalent influenza vaccine (TIV)
Study: 30843873
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) administration of trivalent influenza vaccine (TIV)
Study: 30843873
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of trivalent influenza vaccine (TIV)
Study: 30538429
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of roflumilast (0.25, 0.375, and 0.5 mg)
Study: 30538429
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of roflumilast (0.375 mg once daily for 11 days)
Study: 27813422
Drug: BI 695501
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 695501 (40 mg subcutaneous dose)
Study: 27813422
Drug: US-approved Humira
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-approved Humira (40 mg subcutaneous dose)
Study: 27813422
Drug: EU-approved Humira
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-approved Humira (40 mg subcutaneous dose)
Study: 19907167
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in combination with rt-PA thrombolysis
Study: 17691590
Drug: Iron(III)‐hydroxide polymaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered with orange juice (enhancer)
Study: 17691590
Drug: Iron(III)‐hydroxide polymaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered with food
Study: 17691590
Drug: Iron(III)‐hydroxide polymaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered during fasting
Study: 17691590
Drug: Iron(III)‐hydroxide polymaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered with black tea (inhibitor)
Study: 11908739
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) as a single agent for three months
Study: 10440409
Drug: Conventional dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dual or triple cyclosporine A immunosuppressive therapy
Study: 7540478
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (2 IU/M2) continued until variant GH production from the placenta was evident.
Study: 7540478
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (2 IU/M2) during pregnancy.
Study: 29261736
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (250mg every 6 h for 10-14 days)
Study: 24028842
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of a medical clown during intravenous catheter insertion
Study: 24028842
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of a medical clown during intravenous catheter insertion
Study: 18987358
Drug: lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenalidomide 10 mg/day
Study: 21753188
Drug: lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenalidomide 5 mg/day
Study: 9143888
Drug: Indirect laser
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect laser treatment (scatter photocoagulation)
Study: 8191269
Drug: Propofol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (15 mg)
Study: 8191269
Drug: Intralipid (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (1.5 mg)
Study: 31776882
Drug: Waitlisted-treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlisted-treatment-as-usual control group
Study: 27405049
Drug: Self-care skills
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-care skills training with solution-focused counselling
Study: 23252878
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg vortioxetine
Study: 18464745
Drug: Irbesartan monotherapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan monotherapy for 12 weeks
Study: 9048788
Drug: CDP571 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (5 mg/kg)
Study: 29360778
Drug: P280 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: P280 (70 g whey protein, 280 kcal)
Study: 29360778
Drug: M280 (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: M280 (14 g protein, 28 g carbohydrate, 12.4 g fat, 280 kcal)
Study: 29360778
Drug: M504 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: M504 (70 g protein, 28 g carbohydrate, 12.4 g fat, 504 kcal)
Study: 16632108
Drug: VDV3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDV3 vaccine
Study: 12791632
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg Zn daily during the second half of pregnancy)
Study: 10561270
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation chemotherapy (CC)
Study: 8565760
Drug: Sulglycotide 400
Normalized name: sulglicotide
DrugBank: Sulglicotide (DB13299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulglycotide 400 mg three times a day for one year
Study: 2007672
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole (1% cream), applied twice daily
Study: 2007672
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline (250 mg, taken twice daily)
Study: 6350473
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg acyclovir intravenously three times daily for five days
Study: 20622200
Drug: Tecarfarin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecarfarin (50 mg)
Study: 20622200
Drug: Warfarin (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (17.5 mg)
Study: 31773199
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation
Study: 31773199
Drug: No bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bowel preparation
Study: 12928713
Drug: morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.2 mg IT in addition to hyperbaric bupivacaine 10 mg IT
Study: 12928713
Drug: hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric bupivacaine 10 mg IT
Study: 11754675
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 microgram total dose, 2 puffs in each nostril once daily for 21 days)
Study: 11754675
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (2 puffs in each nostril once daily for 21 days)
Study: 9481097
Drug: Azathioprine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (1.5 mg/kg/day) with prednisolone (2 mg/kg on alternate days)
Study: 9481097
Drug: Pulse intravenous
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse intravenous cyclophosphamide (500 mg/m2 body surface area monthly) with prednisolone (2 mg/kg on alternate days)
Study: 3743615
Drug: oxprenolol Oros,
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxprenolol Oros, 16/260 mg/day
Study: 3743615
Drug: atenolol, 100
Normalized name: Atenolol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol, 100 mg/day
Study: 26709241
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (21 g/day for 8 weeks)
Study: 16920847
Drug: Lignan complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignan complex (500 mg/d of SDG)
Study: 14682107
Drug: Postexcisional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postexcisional radiation therapy
Study: 14682107
Drug: No radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiation therapy (excision alone)
Study: 8981490
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (methylcobalamin; 0.5 mg/day intravenously for 11 days, followed by 2 mg x 3/day orally for 7 days)
Study: 3921146
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment from a general practitioner
Study: 3921146
Drug: Crossover behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover behavioural treatment from the nurse
Study: 3921146
Drug: Dropped out
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dropped out or refused therapy
Study: 31672711
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of a progestogen-only pill (POP, desogestrel) plus rapid access to a local sexual and reproductive health (SRH) clinic.
Study: 11146310
Drug: Calcitriol therapy
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol therapy as a single weekly dose of 0.08 microg/kg b.w. (Group A)
Study: 11146310
Drug: Calcitriol therapy
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol therapy divided into two equal doses (Group B)
Study: 11146310
Drug: Calcitriol therapy
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol therapy divided into three doses (Group C)
Study: 18623907
Drug: Meningitis B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningitis B vaccine (two doses)
Study: 14572890
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isosorbide mononitrate, given intravaginally 12 h before induction
Study: 23488643
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DHEA
Study: 10372727
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DHEA
Study: 16483520
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of SF-36
Study: 7983296
Drug: Face-to-face administration
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face administration of SF-36
Study: 16483520
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of SF-36
Study: 1417339
Drug: Indirect endolymphatic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect endolymphatic therapy with bicillin‐3
Study: 1417339
Drug: Routine penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine penicillin therapy
Study: 6198058
Drug: Quadruple chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple chemotherapy
Study: 29953575
Drug: Hypertonic saline-hydroxyethyl
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline-hydroxyethyl starch (HS-HES) solution
Study: 27673385
Drug: Epinephrine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.1 to 0.2 to 0.3 μg/kg/min)
Study: 27673385
Drug: Dopamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (10 to 15 to 20 μg/kg/min)
Study: 25670057
Drug: Synergy™ drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy™ drug-eluting stent (EES)
Study: 1789096
Drug: Astigmatism treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astigmatism treatment
Study: 28503750
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg daily for 26 weeks
Study: 27838115
Drug: Sevoflurane (2.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (2.5-4 percent) inhalation in Group S (n=7)
Study: 27838115
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (1-2mg·kg-1·min-1) in Group P (n=7)
Study: 17466854
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (n = 20) received 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub‐Tenon's space
Study: 17466854
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (n = 20) received the same combination injected into the anterior sub‐Tenon's space
Study: 15754633
Drug: Control (pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pharmacological treatment only)
Study: 7586997
Drug: Med 15
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Med 15 (1.200 mg for 2 days, then 600 mg for 13 days)
Study: 7586997
Drug: Piroxicam (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (same dosage regimen as Med 15)
Study: 6986027
Drug: Antacid (Mylanta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Mylanta II, 30 ml every hour)
Study: 6986027
Drug: Cimetidine with
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine with antacid titration
Study: 23964752
Drug: DDEA 1.16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDEA 1.16% gel (2 g, 4x/day, for 5 days)
Study: 21423115
Drug: Vasoactive, antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive, antioxidant treatment and neuromidin (15 mg in solution for 10 days, then 20 mg three times a day for 2 months)
Study: 21423115
Drug: Vasoactive and
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive and antioxidant treatment
Study: 19684171
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of spread with a target dose of 1 x 10(9) CFU of L. reuteri DSM 17938
Study: 19684171
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of spread with a target dose of 5 x 10(9) CFU of L. rhamnosus GG
Study: 19684171
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of placebo spread
Study: 11448297
Drug: Sertraline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline therapy
Study: 11020092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and sertraline
Study: 9432270
Drug: Bovine pericardium
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine pericardium patch angioplasty
Study: 1469180
Drug: Midazolam (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (continuous infusion of 0.02‐0.20 mg/kg/h)
Study: 6325909
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated Oka/Merck varicella vaccine
Study: 29190319
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy (RT) with concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Study: 25687834
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (autogenous split‐thickness skin implant)